Search clinical trials for: CT001

Total 56 results

Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
Shanghai Vinnerna Biosciences Co., Ltd.

Recruiting

A Real-World Study of JT001 for COVID-19

COVID-19

China
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection

Tuberculosis

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Multiple Myeloma | Primary Plasma Cell Leukemia
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Gastric Cancer | Pancreatic Cancer

United States, Canada
Shanghai JunTop Biosciences Co., LTD
Sponsor GmbH

Terminated

JT001 (VV116) for the Early Treatment of COVID-19

Mild to Moderate COVID-19

China, Hong Kong
BBraun Medical SAS

Completed

Multicenter Study to Describe the Performance of the AOS-C2001-B Device in Patients With Colostomy

Colostomy Stoma

France
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Recruiting

The Mass Balance Study of [14C]JT001

Healthy Subjects

China
Pearl Therapeutics, Inc.

Completed

PT003 MDI Dose Confirmation Study

Chronic Obstructive Pulmonary Disease

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

JT001 (VV116) for the Treatment of COVID-19

Mild to Moderate COVID-19

China
Accendatech USA Inc.
Avance Clinical Pty Ltd.; C3 Research Associates

Recruiting

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme(GBM)

United States
Cessatech A/S

Not yet recruiting

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients

Pain
Cessatech A/S

Completed

Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures

Analgesia

Denmark
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Enrolling by invitation

A Long-term Follow-up Study in Participants Who Received CTX001

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Canada, Italy, United Kingdom, Germany
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Elderly Chinese Subjects With Underlying Diseases

Elderly Subjects With Underlying Diseases

China
Johnson & Johnson Surgical Vision, Inc.

Active, not recruiting

Proof-of-concept Study for a New Intraocular Lens, MODEL C0001

Cataract

France
Revance Therapeutics, Inc.

Completed

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Terminated

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Moderate to Severe COVID-19

China, Uzbekistan
Revance Therapeutics, Inc.

Completed

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Lateral Canthal Lines

United States
Revance Therapeutics, Inc.

Completed

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
Retrotope, Inc.

Completed

A First in Human Study of RT001 in Patients With Friedreich's Ataxia

Friedreich's Ataxia

United States
CARsgen Therapeutics Co., Ltd.
Fudan University

Recruiting

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Pancreatic Cancer

China
Retrotope, Inc.

Completed

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

Friedreich's Ataxia

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function

Subjects With Liver Function Injury | Normal Liver Function Subject

China
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, United Kingdom, Germany, Canada, Italy
Retrotope, Inc.

Active, not recruiting

A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Infantile Neuroaxonal Dystrophy

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Sickle Cell Disease
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Italy, Germany
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, Germany, Italy, United Kingdom, Canada
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Sickle Cell Disease | Hemoglobinopathies | Hematological Diseases | Hydroxyurea Failure | Hydroxyurea Intolerance

United States, Italy, United Kingdom, Germany
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Sickle Cell Disease | Hemoglobinopathies | Hematological Diseases

United States, Belgium, Canada, France, Germany, Italy, United Kingdom
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

COPD, Chronic Obstructive Pulmonary Disease

Belgium
Retrotope, Inc.

Recruiting

RT001 in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

Netherlands, Estonia, Latvia, Sweden
Retrotope, Inc.

Recruiting

RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY

Progressive Supranuclear Palsy

Germany
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

United States
Revance Therapeutics, Inc.

Completed

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
Carrick Therapeutics Limited

Completed

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Advanced Solid Malignancies

United States, United Kingdom
Cessatech A/S

Completed

Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001

Pain

Denmark
Cessatech A/S
Smerud Medical Research International AS; Dantrials Aps

Completed

Study of CT001 in Healthy Volunteers

Bioavailability

Denmark
VarmX B.V.

Completed

Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

Coagulation Disorder

Netherlands
Vigonvita Life Sciences

Completed

Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

COVID-19

China
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Revance Therapeutics, Inc.

Completed

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Lateral Canthal Lines

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand

Search clinical trials for: CT001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations